Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression

Nephrology Dialysis Transplantation

Volumn 34, Issue 5, 2019, Pages 783-794

  Gonzalez, Austin ^a   Krieg, Richard ^b   Massey, Hugh D ^b   Carl, Daniel ^a   Ghosh, Shobha ^a   Gehr, Todd W B ^a   Ghosh, Siddhartha S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

chronic renal failure; diabetic kidney disease; gut; nephrectomy; short chain fatty acid

Indexed keywords

5' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; BUTYRIC ACID; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CLAUDIN 1; CREATININE; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 10; MUCIN; MUCIN 2; PROTEIN KINASE; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG; UREA; ANTIHISTAMINIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DUODENUM; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEINURIA; RAT; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; METABOLISM; PERMEABILITY; PHYSIOLOGY;

ANIMALS; BUTYRIC ACID; DISEASE MODELS, ANIMAL; HISTAMINE ANTAGONISTS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INTESTINAL MUCOSA; MALE; MUCINS; PERMEABILITY; RATS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85060410773     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfy238     Document Type: Article

References (51)

1. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83: 1010-1016
2. Nallu A, Sharma S, Ramezani A et al. Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res 2017; 179: 24-37
3. Vaziri ND, Wong J, Pahl M et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013; 83: 308-315
4. Cani PD, Osto M, Geurts L et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-288
5. Ghosh SS, Righi S, Krieg R et al. High fat high cholesterol diet (western diet) aggravates atherosclerosis, hyperglycemia and renal failure in nephrectom-ized LDL receptor knockout mice: role of intestine derived lipopolysaccha-ride. PLoS One 2015; 10: e0141109
6. Vaziri ND, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2016; 31: 737-746
7. Vaziri ND, Yuan J, Nazertehrani S et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013; 38: 99-103
8. Vaziri ND, Yuan J, Rahimi A et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012; 27: 2686-2693
9. Johansson ME, Hansson GC. Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol 2016; 16: 639-649
10. Andersen K, Kesper MS, Marschner JA et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol 2017; 28: 76-83
11. Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. Tissue Barriers 2015; 3: e982426
12. McGuckin MA, Lindén SK, Sutton P et al. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011; 9: 265-278
13. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014; 12: 661-672
14. Sharon G, Garg N, Debelius J et al. Specialized metabolites from the micro-biome in health and disease. Cell Metab 2014; 20: 719-730
15. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15: 474-479
16. Miao W, Wu X, Wang K et al. Sodium butyrate promotes reassembly of tight junctions in Caco-2 monolayers involving inhibition of MLCK/MLC2 pathway and phosphorylation of PKCb2. Int J Mol Sci 2016; 17: 1696
17. Finnie IA, Dwarakanath AD, Taylor BA et al. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995; 36: 93-99
18. Gao Z, Yin J, Zhang J et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509-1517
19. Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with met-formin. Chem Biol Interact 2016; 254: 124-134
20. Wong J, Piceno YM, DeSantis TZ et al. Expansion of urease-and uricase-containing, indole-and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014; 39: 230-237
21. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014; 25: 657-670
22. Yadav H, Lee JH, Lloyd J et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 2013; 288: 25088-25097
23. Zavattaro M, Caputo M, Samà MT et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 2015; 50: 620-626
24. von Scholten BJ, Hansen TW, Goetze JP et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complicat 2015; 29: 670-674
25. Kieffer DA, Piccolo BD, Vaziri ND et al. Resistant starch alters gut micro-biome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 2016; 310: F857-F871
26. Vaziri ND, Liu SM, Lau WL et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 2014; 9: e114881
27. Yang HC, Zuo Y, Fogo AB. Models of chronic kidney disease. Drug Discov Today Dis Models 2010; 7: 13-19
28. Chapagain A, Caton PW, Kieswich J et al. Elevated hepatic 11b-hydroxyste-roid dehydrogenase type 1 induces insulin resistance in uremia. Proc Natl Acad Sci USA 2014; 111: 3817-3822
29. Hosoya K, Minakuchi H, Wakino S et al. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney Int 2015; 87: 749-760
30. Lin HV, Frassetto A, Kowalik EJ et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012; 7: e35240
31. Ghosh SS, Massey HD, Krieg R et al. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation. Am J Physiol Renal Physiol 2009; 296: F1146-F1157
32. Ghosh SS, Bie J, Wang J et al. Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/-mice-role of intestinal permeability and macrophage activation. PLoS One 2014; 9: e108577
33. Ghosh SS, Krieg R, Massey HD et al. Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase. Am J Physiol Renal Physiol 2012; 302: F439-F454
34. Kameyama A, Dong W, Matsuno YK. Succinylation-Alcian blue staining of mucins on polyvinylidene difluoride membranes. Methods Mol Biol 2015; 1314: 325-331
35. Huang Y, de Boer WB, Adams LA et al. Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int 2013; 33: 1249-1256
36. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772
37. Guttman JA, Finlay BB. Tight junctions as targets of infectious agents. Biochim Biophys Acta 2009; 1788: 832-841
38. Joshi S, Kumar S, Bafna S et al. Genetically engineered mucin mouse models for inflammation and cancer. Cancer Metastasis Rev 2015; 34: 593-609
39. Cobo ER, Kissoon-Singh V, Moreau F et al. MUC2 mucin and butyrate contribute to the synthesis of the antimicrobial peptide cathelicidin in response to Entamoeba histolytica-and dextran sodium sulfate-induced colitis. Infect Immun 2017; 85
40. Hasnain SZ, Tauro S, Das I et al. IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology 2013; 144: 357-368.e359
41. Schwerbrock NM, Makkink MK, van der Sluis M et al. Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. Inflamm Bowel Dis 2004; 10: 811-823
42. Sun X, Yang H, Nose K et al. Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function in a mouse model of total paren-teral nutrition. Am J Physiol Gastrointest Liver Physiol 2008; 294: G139-G147
43. Aznar N, Patel A, Rohena CC et al. AMP-activated protein kinase fortifies epithelial tight junctions during energetic stress via its effector GIV/Girdin. Elife 2016; 5: e20795
44. McIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 133-141
45. Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013; 62: 2164-2172
46. Peng L, Li ZR, Green RS et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein ki-nase in Caco-2 cell monolayers. J Nutr 2009; 139: 1619-1625
47. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174
48. Duca FA, Côté CD, Rasmussen BA et al. Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production in rats. Nat Med 2015; 21: 506-511
49. Khan S, Jena G. The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention. Epigenomics 2015; 7: 669-680
50. Jin T, Weng J. Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. Am J Physiol Endocrinol Metab 2016; 311: E620-E627
51. Jiang S, Xie S, Lv D et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep 2017; 7: 2870